Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sezary Syndrome 1Sarcoma, Synovial 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1HIV Infections 1Colorectal Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

Doxorubicin 4Gemcitabine 3pembrolizumab 2pazopanib 2fludarabine 2cixutumumab 2brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Docetaxel 2Cyclophosphamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1tazemetostat 1sotigalimab 1soblidotin 1romidepsin 1reolysin 1perifosine 1pasireotide 1lorvotuzumab mertansine 1ixabepilone 1interferon gamma-1b 1exatecan 1durvalumab 1drozitumab 1atezolizumab 1Trastuzumab 1Trabectedin 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Synovial × interferon gamma-1b × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡